Head-to-head · free
Becton, Dickinson and Company vs Dianthus Therapeutics, Inc.
BDX vs DNTH — return on capital, cash generation, margins and balance sheet side by side.
BDX
5 / 6
measures where BDX leads
DNTH
1 / 6
measures where DNTH leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | BDX · FY2025 | DNTH · FY2025 |
|---|---|---|
| Revenue | $21.8B | $2.0M |
| Net income | $1.7B | (162.3M) |
| Revenue growth (yearly, multi-year) | 1.9% | -67.3% |
| Free cash flow | — | — |
| Free cash flow margin | — | — |
| Net cash / (debt) | — | — |
| ROIC | 5.1% | — |
| Return on equity | 6.5% | -38.4% |
| Gross margin | 45.4% | — |
| Operating margin | 13.7% | -8739.3% |
| Net debt / EBITDA | 3.68x | 0.29x |
Figures are as reported by each company; latest fiscal year shown.
Where Becton, Dickinson and Company's cash went (FY2025)
- Capital spending
- $760.0M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Dianthus Therapeutics, Inc.'s cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free